中国当代医药2025，Vol.32Issue(27)：70-74,5.DOI:10.3969/j.issn.1674-4721.2025.27.15
EGFR-TKIs联合化疗一线治疗表皮生长因子受体/肿瘤抑制因子p53基因共突变晚期非小细胞肺癌的效果和安全性
Efficacy and safety of EGFR-TKIs combined with chemotherapy in first-line treatment of advanced non-small cell lung cancer with epidermal growth factor receptor/tumor protein p53 gene co-mutation
摘要
Abstract
Objective To explore the efficacy and safety of EGFR-TKIs combined with the first-line treatment method of chemotherapy for advanced non-small cell lung cancer with epidermal growth factor receptor/tumor protein p53(EGFR/TP53)gene co-mutation.Methods A total of 66 patients with advanced non-small cell lung cancer with EGFR/TP53 gene co-mu-tation admitted to the Department of Oncology of Xinyu People's Hospital from January 2023 to December 2024 were retrospectively selected as the research objects,they were divided into the monotherapy group and the combination group according to the treatment plan,with 33 cases in each group.The monotherapy group was treated with EGFR-TKIs,the combination group adopted the first-line treatment method of chemotherapy combined with EGFR-TKIs.The therapeutic effects and the occurrence of adverse reactions of the two groups of patients were compared.Results The objective response rate(ORR)in the combination group was higher than that in the monotherapy group,with statistically significant difference(P＜0.05).There were no statistically significant differences in the disease control rate(DCR),and total incidence of adverse reactions between the two groups of patients(P＞0.05).Conclusion The combined treatment regimen of EGFR-TKIs and the first-line treatment method of chemotherapy has superior effect.When applied to patients with advanced non-small cell lung cancer with EGFR/TP53 gene co-mutation,the overall effect is ideal,the safety is controllable,and it does not significantly increase the treatment risk.It is a treatment regimen that can be referred to.关键词
EGFR-TKIs/化疗/非小细胞肺癌/基因共突变Key words
EGFR-TKIs/Chemotherapy/Non-small cell lung cancer/Gene co-mutation分类
医药卫生引用本文复制引用
何丽,李小兵,杨芸..EGFR-TKIs联合化疗一线治疗表皮生长因子受体/肿瘤抑制因子p53基因共突变晚期非小细胞肺癌的效果和安全性[J].中国当代医药,2025,32(27):70-74,5.基金项目
江西省卫生健康委科技计划项目(202311789) （202311789）
江西省新余市科技计划项目(20233090860). （20233090860）
